Nabiximols: Multiple Sclerosis
Commons · Question 27242 · Tabled 4 Sep 2026 · Department of Health and Social Care · Official record
Answered 11 Sep 2026
Question
Asked by Yasmin Qureshi
To ask the Secretary of State for Health and Social Care, whether she has asked NICE to review the position of nabiximols in the treatment pathway for MS-related spasticity, including its use earlier in the pathway.
Answer
Answered by James Frith, 11 Sep 2026
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spastici...